Q&A with Georgios Grammatikos, MD: Mass Spectrometry as Lipid ID'ing Method of The Future
Georgios Grammatikos, MD, commented at The International Liver Congress 2015 in Vienna, Austria, "We do think in liver diseases we show the opening of this topic in chronic hepatopathy and we do believe mass spectrometric methods -- in order to identify the levels of single lipids-- as one method of the future."
Damage to the Hepatic Antioxidant System
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, discussed his hope for hepatologists to better understand the mechanisms that lead from fatty liver to steatohepatitis and subsequently from steatohepatitis to cirrhosis at The International Liver Congress 2015.
Hepatitis C: Testing Has a Long Way to Go
The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
Hepatitis C: Interferon's Return Stirs Controversy
The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.
Weaning Transplant Patients from Immunosuppressive Drugs
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.
Weighing Liver Transplants for Polycystic Patients
One cure for polycystic liver disease is a liver transplant-but since the disease is not fatal (the liver continues to do its job despite the problems the condition causes for patients), physicians face a treatment dilemma. A Belgian team offers an objective way to make the decision.
Mechanisms Involved in Liver Injury: A Closer Look
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.
Liver Disease Takes Toll on the Heart
When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.
Positive Results on Ledipasvir-Sofosbuvir
French researchers found that patients with hepatitis C infections due to genotypes 4 and 5 did well on a combination of ledipasvir and sofosbuvir (Harvoni/Gilead.) The drug got FDA approval last year but since then there have been few reports on how well it is doing in the real world.
Liver Disease: A Puzzle with Many Pieces
In this video interview, Palak Trivedi, BSc, MBBS, MRCP, from the University of Birmingham Centre for Liver Research, United Kingdom, discussed the implications his research findings have for IBD patients at The International Liver Congress 2015 in Vienna, Austria.
Liraglutide Shows Promise in Liver Disease
So far there are no approved pharmaceuticals for treating a common liver disease, non-alcoholic steatohepatitis (NASH). But in a second encouraging drug development reported at the International Liver Congress in Vienna, Austria this morning, Austria, researchers said they like what they see in a trial of Liraglutide (Saxenda/ NovoNordisk).